THE HYPEREOSINOPHILIC SYNDROMES AND MEPOLIZUMAB

描述（由申请人提供）：术语嗜酸性粒细胞增多综合征（HES）是指血液嗜酸性粒细胞升高的患者谱。在过去的二十年中，某些类别的患者已被确认为HES亚组。例如，与嗜酸性粒细胞增多症相关的发作性血管性水肿综合征、结节综合征、嗜酸性粒细胞增多症、风湿病、皮炎和肿胀、与T细胞克隆相关的HES和骨髓增生性变体已被认识。具有产生TH 2细胞因子的T细胞克隆的患者显示L-5产生的证据，并且IL-5刺激骨髓产生和嗜酸性粒细胞的活化。美泊利珠单抗是一种高亲和力、特异性、人源化的IL-5单克隆抗体，可快速清除外周血中的嗜酸性粒细胞。这种抗体已被用于患有多种疾病的患者，包括哮喘，并且它明显没有副作用。随附的核心临床方案描述了一项美泊利珠单抗治疗HES的试验;该机制建议旨在了解美泊利珠单抗应答的基本机制。具体来说，我们将：1。确定mepolizumab是否调节T细胞功能，包括其分化和细胞因子的产生。2.测试美泊利单抗治疗是否抑制治疗患者的嗜酸性粒细胞活化、细胞因子产生和嗜酸性粒细胞上IL-5受体的表达。3.确定美泊利单抗是否揭示了迄今为止尚未认识到的HES异质性。总体而言，这是一个独特的和前所未有的机会，进行一项多中心研究，涉及具有相当经验的研究者，以研究抗IL-5给药的影响，并确定哪些嗜酸性粒细胞活化标志物与疾病活动性最相关。以前的研究主要来自单一机构，这将是第一个多中心研究。我们预计，通过确定基本上所有HES亚型及其频率，通过确定抗IL-5改变HES免疫学基础的能力，通过鉴定和调查对抗IL-5无反应的患者，以及通过鉴定可以用抗IL-5有效治疗的患者的特征，这些结果将为这种疾病提供新的线索。

DESCRIPTION (provided by applicant): The term, hypereosinophilic syndromes (HES), refers a spectrum of patients with elevated blood eosinophils. Over the past two decades, certain categories of patients have been recognized as HES subgroups. For example, the syndromes of episodic angioedema associated with eosinophilia, the syndrome of nodules, eosinophilia, rheumatism, dermatitis and swelling, HES associated with T cell clones, and the myeloproliferative variant have been recognized. Patients with T cell clones producing TH2 cytokines show evidence of L-5 production and IL-5 stimulates bone marrow production and activation of eosinophils. Mepolizumab is a high-affinity, specific, humanized monoclonal antibody to IL-5 which rapidly depletes eosinophils from the peripheral blood. This antibody has been administered to patients with several diseases, including asthma, and it is remarkably free of side-effects. The accompanying core clinical protocol describes a trial of mepolizumab for the treatment of HES; this mechanistic proposal seeks to understand the basic mechanisms underlying the response to mepolizumab. Specifically, we will: 1. Determine whether mepolizumab modulates T-cell functions, including their differentiation and cytokine production. 2. Test whether mepolizumab treatment suppresses eosinophil activation, cytokine production and expression of the IL-5 receptor on the eosinophils of treated patients. 3. Determine whether mepolizumab reveals heterogeneity in HES not heretofore recognized. Overall, this is a unique and unprecedented opportunity to conduct a multicenter study involving investigators with considerable experience to investigate the effects of anti-IL-5 administration and to determine which markers of eosinophil activation are best correlated with disease activity. Previous studies have largely been from single institutions, and this will be the first multicenter study. We anticipate the results will shed new light on this disease by defining essentially all HES subtypes and their frequencies, by determining the ability of anti-IL-5 to alter the immunological bases of HES, by identifying and investigating patients not responsive to anti-IL-5 and by identifying the characteristics of patients who can be effectively treated with anti-IL-5.